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Abstract: The recepteur d’origine nantais (RON) is a member of MET family of receptor tyrosine kinase (RTKs), an 
overexpression of which has been observed in several cancers. The expression of RON gene is required during embryonic 
development and also plays critical roles in regulating macrophage inflammatory response. In CRC, the overexpression of 
moderate RON activity contributes to their oncogenic potential by regulating several key processes such as proliferation, 
motility and resistance to apoptosis. Interestingly, an aberrant RON expression is often associated with the generation of 
several splice variants with unique transforming activities. The targeting of RON signaling pathway by the use of mono-
clonal antibodies and small-molecule inhibitors has shown promising therapeutic results in animal models. The present ar-
ticle aims at summarizing the current understanding of RON kinase in CRC.  
Keywords: Colorectal cancer, Macrophage, Receptor Tyrosine kinase, Ron kinase, Splice Variants, Therapeutic Targeting. 
INTRODUCTION 
 Receptor Tyrosine Kinases (RTKs) are cell-surface re-
ceptors for several growth factors, cytokines and hormones 
[1]. Signaling by RTKs is one of the major mechanisms of 
intracellular communication during embryonic development 
and physiological processes. However during pathological 
conditions such as cancer either inappropriate activation or 
disruptions of regulatory mechanisms lead to constitutively 
activated pathways [2, 3]. RON belongs to MET proto-
oncogene family and shares significant structural and func-
tional homology with cMET [4]. There is also a high degree 
of homology between MSP (Macrophage stimulating pro-
tein, the ligand for RON) and HGF/SF (Hepatocyte-growth 
factor/Scatter factor, the ligand for RON) [5].  
 RON gene is embryonic lethal in pre-implantation stage 
suggesting its critical role in embryonic development [6]. In 
adults a moderate RON gene expression is observed in sev-
eral epithelial tissues and macrophages [5, 7]. The activation 
of RON by serum-protein MSP under physiological condi-
tions becomes leaky in cancer consequent to several chromo-
somal aberrations which lead to a ligand-independent activa-
tion of RON [8]. Thus an aberrant overexpression of RON is 
observed in many cancers such as colon, breast and pancre-
atic cancers [9-13]. RON overexpression has been shown 
important in driving tumorigenesis and is associated with 
poor prognosis. Interestingly overexpression of RON is often 
associated with the generation of splice variants each with a 
unique expression profile and characteristic structural and 
functional properties [14-16].  
 Colorectal cancer (CRC) is the third most common can-
cer and second leading cause of cancer related deaths in the 
United States [17-19]. Although a number of screening  
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methods have been developed, their effectiveness is limited 
due to lack of awareness and financial constraints [19, 20]. 
Metastasis largely determines the survival time of patients 
and accounts for the majority of CRC deaths [21]. Upon me-
tastasis surgical resection is limited while radiation and che-
motherapy are only palliative. A molecular understanding of 
the phenomenon is thus urgently warranted to prolong the 
survival time of CRC patients with distant metastasis.  
 Previous studies have demonstrated the aberrant RON 
expression in majority of CRC patients [10, 22, 23]. Studies 
from our own laboratory and others have shown that RON 
contributes to the malignant and invasive phenotype of CRC 
[24]. RON has been shown to regulate several key processes 
in colon tumor progression and also plays active role in EMT 
which is analogous its role in embryonic development [25]. 
The function of RON in EMT is of particular clinical interest 
as the transition from epithelial to mesenchymal phenotype 
is a major determinant of metastatic dissemination [26]. Thus 
targeting RON is expected to have significant therapeutic 
efficacy in limiting the spread of metastatic CRC. Several 
RTK inhibitors have proven their success clinically in the 
past further encouraging the studies on the therapeutic utili-
zation of RON RTK [1, 27, 28]. The characteristics of RON 
such as high prevalence in CRC and cell-surface RTK activ-
ity make it an important candidate for anti-cancer therapies. 
Further studies are warranted to develop and test the utility 
of targeting RON signaling in CRC. The article summarizes 
our present understanding on RON in pathogenesis of CRC. 
THE BIOLOGY OF RON  
 The cloning of human RON cDNA was done less than 
two decades ago in 1993 from the library of human keratino-
cytes [29]. The frequently altered RON gene in cancers is 
16.8 kb and located on chromosome 3p21 [29]. The mature 
RON receptor is 180 kDa protein with 40 kDa extracellular 
Į- chain and 150 kDa ȕ- chain with extracellular, transmem-
brane and cytoplasmic domains and intrinsic kinase activity 
[5, 30]. The two Į- and ȕ- chains are linked by a disulphide 
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bond. The extracellular domain of RON consists of well de-
fined sema (N-terminal semaphoring), PSI (plexin sema-
phore-and integrin) and four immunoglobulin-like IPT do-
mains. The only identified ligand for RON receptor is MSP 
(macrophage stimulating protein) [31]. The gene for MSP is 
located at a similar position as RON on chromosome 3p21 
[32]. MSP is synthesized by hepatocytes and circulates in 
blood as inactive precursor pro-MSP [33]. The mature het-
erodimeric MSP consisting of a 60 kDa Į-chain and 30 kDa 
ȕ-chain is generated by proteolytic cleavage at dibasic argin-
ine–valine (R554–V555). The receptor-binding site of MSP is 
located in the MSP ȕ-chain. The Į-chain contains four triple 
disulfide loop structures called kringle domains. The ȕ-chain 
contains a serine protease-like domain in which there is sub-
stitution of three amino acids making it devoid of any enzy-
matic activities [34].  
 The expression of RON gene is observed early in the 
embryonic development. In mice homozygous loss of RON 
gene (Ron-/-) leads to death prior to ED (embryonic day) 6.5 
suggesting that RON is critical in embryonic development 
[6]. In adult tissues the expression of RON gene in epithelial 
cells enhances their adhesion and motility. For instance 
RON-MSP signaling increases the ciliary beat of nasal mu-
cosal cells [35] and plays role in sperm motility in epithe-
lium of the epididymis [36]. In tissue macrophages RON 
regulates the extent of their activation and inflammatory re-
sponse [7].  
RON SPLICE VARIANTS  
 An interesting and unique phenomenon in RON mediated 
tumorigenesis is the existence of splice variants. Intriguingly 
wild-type (wt) RON does not have cellular transforming ac-
tivities on ectopic expression in NIH3T3 cells while several 
other variants isolated and cloned from tumor samples in-
duce tumorigenic properties upon transformation [14, 37]. In 
CRC in addition to the overexpression of wt RON there is 
also existence of splice variants in certain tumor tissues. The 
three splice variants that have been detected are namely 
RONǻ165, RONǻ160, and RONǻ155 the expression and 
occurrence of which has been confirmed by the use of anti-
bodies targeting different regions of RON [10, 23]. The 
splice variants have been shown to play important roles in 
the progression of CRC in vivo. For instance RONǻ160 and 
RONǻ155 when transfected in NIH3T3 cells have the ability 
to induce focus formation and anchorage independent 
growth. Further NIH3T3 cells expressing RONǻ160 or 
RONǻ155 form tumors in athymic nude mice and show dis-
tant metastasis to lungs [10]. The variant RONǻ160 was 
initially discovered in HT29 colon cancer cells [16] and later 
confirmed in tumor samples from CRC patients. These three 
RON splice variants are generated by deletions in extracellu-
lar ȕ-domain leading to the abnormal dimerization. A com-
parative analysis of the different variants of RON and their 
oncogenic potential has been done in Table 1. Interestingly 
RON mutants maintain a high level of expression in CRC by 
resisting the process of receptor endocytosis and ubiquityla-
tion which is observed in wt RON [38, 39]. 
 Recently a naturally occurring antagonist of RON 
(RONǻ85) was identified in CRC and other cancers. 
RONǻ85 is the soluble form of RON which act by compet-
ing with wt RON for MSP binding and signaling. It is gener-
ated with an insertion of 49 nucleotides between exons 5 and 
6 which introduces a premature stop codon leading to the 
formation of a truncated 85 kDa RON variant consisting of 
entire 35 kDa Į-chain and a 45 kDa partial extracellular ȕ-
chain. The protein comprises a sema domain, hinge motif 
and portion of the first IPT unit. Interestingly the variant 
RONǻ85 was not translated in cancer cells but demonstrated 
an inhibitory activity when used as a recombinant protein. 
RONǻ85 inhibits ERK1/2 and AKT phosphorylation and 
tumorigenic properties of CRC cells [40]. The study under-
scores the complexity in regulation of RON translation in 
cancer cells and suggests an alternative approach for RON 
targeted therapy.  
 The investigation whether a mutation in the RON kinase 
domain contributes to the constitutive activity in colon can-
cer cells was done in a panel of five carcinoma cell lines - 
HT29, DLD-1, HCT116, SW620 and SW837. There were no 
mutations found but a single-nucleotide polymorphism 
(A4031G) in HT29 and SW620 cells [9]. Though the pres-
Table 1. The Different Splice Variants of RON and their Biological Properties in CRC 
Structure Biological Properties 
Name Cleavage Į chain 
(kDa) 
E Chain 
(kDa) 
Deletion/ 
Insertion 
No. of aa De-
leted/Inserted 
Cellular Local-
ization 
Activation 
Scatter 
Effect 
Oncogenic 
Potential 
wt Ron(180 
kDa)  
Yes 40 145 None None Cell surface MSP ligand 
binding 
Yes Yes 
Ronǻ165 No 165 KD single chain 
precursor 
Exon 11 Del-49 Intracellular Constitutive 
active 
Yes No 
Ronǻ160 Yes 40 135 Exon 5,6 Del-109 Cell surface Constitutive 
active 
Yes Yes 
Ronǻ155 No 40 125 Exon 5, 6,11 Del-158 Intracellular Constitutive 
active 
Yes Yes 
RONE5/6in Yes 35 45 Exon 5,6 Ins-20 Cell surface MSP ligand 
binding 
Yes No 
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ence of mutations has not been investigated in the tumor 
tissues from CRC patients these initial findings indicate that 
receptor overexpression leading to dimerization and activa-
tion is the major mechanism of RON activity in CRC.  
 In order to decipher the molecular mechanisms of cancer 
specific RON aberrant splicing, the role of SF2/ASF splicing 
factor was investigated [41]. SF2/ASF on binding to the 
regulatory ‘control cassettes’ in Exon12 promotes inclusion 
of Exon11. Thus by regulating the ratio of wt RON and 
RONǻ165 transcripts SF2/ASF regulates the tumorigenic 
potential of the colon cancer cells. Overexpression and 
knockdown studies on SF2/ASF exhibited a phenotype 
which is similar to that of RONǻ165 further emphasizing the 
role of SF2/ASF in regulating its splicing [41]. In another 
study the role of first IPT domain in regulating the tumori-
genic potential of RON was investigated in RONǻ160 and 
RONE5/6in which are generated by 109 amino acid deletion 
and 20 amino acid insertion respectively between Exon5 and 
Exon6 [42]. It was observed that the two variants are quite 
different functionally - though RONǻ160 showed constitu-
tively active signaling, the activation of RONE5/6in required 
stimulation with ligand MSP. Further RONǻ160 showed 
higher tumorigenic potential and resistance to antibody me-
diated receptor internalization as compared to RONE5/6in[42]. 
These findings therefore underscore the importance of IPT 
units in RON signaling. Further studies need to be done to 
comprehend fully the mechanisms of splice variants genera-
tion and a post-transcriptional regulation which translate to 
abnormal proteins thereby contributing to the malignant phe-
notype.  
ONCOGENIC POTENTIAL OF RON  
 RON regulates several key processes in tumor develop-
ment such as proliferation, motility and invasion [22, 23]. 
Several cancers of epithelial origin show a marked elevation 
in RON expression contributing to their malignant phenotype 
[43]. RON overexpression has high prevalence in CRC 
where majority of tumor tissues and cell lines from primary 
and metastatic CRC are shown to be positive for RON ex-
pression [43]. It is noteworthy that the inflammatory condi-
tions such as colitis which are positively correlated with risk 
of CRC also show high RON expression [44].  
 RON was found to be over expressed and constitutively 
active in colon cancer cells as compared to the normal 
epithelial cells or SV40 transformed cells indicating the role 
of RON in malignant phenotype of CRC cells [9]. To eluci-
date whether abnormal RON activation is associated with 
tumorigenic properties in these cells ectopic expression of 
RON was carried out in SV40 transformed CoTr and colon 
cancer cells. It was observed that RON overexpression not 
only increases the migratory and invasive potential in these 
cells but also protects them from apoptotic stimuli [9]. The 
study demonstrates the biological implications of RON over-
expression in pathogenesis of CRC.  
 The differential expression of RON in in vitro studies 
was corroborated by immunohistochemical (IHC) staining of 
the tumor tissues obtained from CRC patients [10]. In addi-
tion to the significantly higher RON staining intensity the 
tumor cells also showed a characteristically distinct pattern 
of staining as compared to the normal colon. In mucosal cells 
from the normal colon a granular expression of RON is ob-
served on the cell surface and cytoplasm whereas in cancer-
ous cells RON expression is diffused throughout the cyto-
plasm. The significance of the changes in expression pattern 
is not understood but may be indicative of their contribution 
to the progression of CRC [10]. An investigation into distinct 
staining patterns between normal and cancerous tissues 
might provide important clues on RON sub-cellular localiza-
tion in physiological and pathological conditions. However it 
should be pointed here that a previous study which used an-
other antibody for staining RON failed to identify any over-
expression of RON protein in CRC [45].  
 In another study a comprehensive transcriptional profil-
ing of RON and other kinases was done in different CRC 
stages - normal colon mucosa, adenomatous polyps, primary 
carcinoma and secondary metastases [46]. Though the study 
demonstrated a positive and differential RON expression in 
tumors derived from primary CRC patients it failed to detect 
any changes in the RON transcript in secondary colon metas-
tasis using RT-PCR based approach [46]. Previous studies 
have emphasized RON is implicated in metastatic phenotype 
of CRC. The discrepancy in the study may be attributed to 
the limitation in the use of RT-PCR based approach of quan-
tification which may not represent the actual difference in 
the expression pattern.  
 Activated RON signaling regulates the characteristic 
hallmarks of malignancy such as cell spreading, dissociation, 
migration and invasive potential [22, 47, 48] The metastatic 
dissemination of epithelial cancers is often accompanied by 
the phenomenon of EMT which encompasses loss of epithe-
lial properties and acquisition of mesenchymal phenotype 
[26]. Thus one of the main mechanisms by which RON fa-
cilitates tumor progression is by playing instrumental role in 
the process of EMT. RON mediated effects are manifested 
by associated morphological changes and in vitro assays. 
The biological functions of RON kinase were studied using 
the gene inactivation and overexpression strategies. When 
normal colonic cells AA/C1 were over expressed with RON 
they exhibited transforming phenotype of colony formation 
and increase in motility [49]. Similarly inactivation of RON 
gene significantly affected the classical tumorigenic proper-
ties of cell proliferation, migration and tumor growth in ani-
mal models of colon cancer [10, 49]. These studies demon-
strate that RON is critical in regulating the malignant proper-
ties of colorectal cancer. A positive RON expression in sev-
eral patient tissues further emphasizes the role of RON 
kinase in regulating tumorigenic potential in CRC. Therefore 
to investigate whether RON has a role in early stage tumori-
genesis, ApcMin/+ mouse was generated with and without 
RON signaling (ApcMin/+ RON+/+ and ApcMin/+ RON-/-) [50]. 
ApcMin/+ mouse is a well studied mouse model in CRC and 
carries a truncation mutation at codon 850 of the Apc gene 
and forms multiple colon tumors. The findings from these 
studies show that in the presence of Apc mutation RON is 
not required for the development and progression of CRC in 
mice.  
RON ACTIVATED SIGNALING PATHWAYS  
 In physiological conditions the binding of RON with its 
ligand MSP causes tyrosine phosphorylation and consequent 
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homo-dimerization and activation of the RON receptor. 
However in CRC RON receptor overexpression or genera-
tion of alternate RON splice variants lead to the ligand-
independent mechanisms for RON activation [8, 51]. It is 
suggested that pre-formed RON homodimers may also be 
activated as the result of cell interaction with the ECM [52]. 
The molecular mechanisms of transducing signals in the ab-
sence or presence of ligand may however be strikingly dif-
ferent. Notably aberrant RON activity also alters the tyro-
sine-phosphorylation of several proteins which may be an-
other mechanism of RON induced cellular transformation. 
The activation of RON RTK regulates a number of signaling 
pathways such as PI3K-AKT, Ras, Src, FAK and ȕ-Catenin 
which in turn regulate several key processes of malignant 
transformation thereby amplifying the tumorigenic potential 
of cells harbouring RON overexpression [53]. The role of 
RON was investigated in relation to deregulated mutant 
PI3K signaling pathway in CRC. Mutations in PIK3CA 
which encodes the p110Į catalytic subunit of PI3K are ob-
served in a large number of CRC patients and HCT116 
which has H1076R gain of function mutation. It was ob-
served that knockdown of RON kinases inhibits the activa-
tion of mutant PI3K and thereby the metastatic potential of 
orthotropically injected colon cancer cells [24]. RON siRNA 
inhibited signaling by ȕ-catenin suggesting the regulation of 
this pathway by RON kinase [49, 50]. However, the effect of 
RON in ȕ-catenin expression and signaling was not observed 
in ApcMin/+ mice. The association of RON with ȕ-catenin and 
PI3K signaling is highly significant with regards to patho-
genesis of CRC - while ȕ-catenin is essential for initiating 
the tumor formation in colon PI3K is important for cell sur-
vival and also the metastatic spread and invasion at later 
stages of CRC progression [54-56]. Thus targeting RON 
RTK signaling may have profound implications in blocking 
several downstream and cross-activated signaling pathways 
Fig. (1) illustrates the RON activated signaling pathways in 
CRC progression.  
THERAPEUTIC TARGETING OF RON KINASE 
 Several cancers show aberrant RTKs signaling which are 
the primary transducers of extracellular growth factor signals 
into the cell. The significance of targeting RTK signaling has 
been successfully demonstrated with a large number of FDA 
approved drugs in clinics [1,28]. In CRC monoclonal anti-
bodies targeting RTKs are against VEGF (Bevacizumab) and 
EGFR (Cituximab and Panitumumab) [57]. An aberrant sig-
naling from RON RTK is observed in majority of CRC pa-
tients and therefore targeting RON holds promise in achiev-
ing appropriate therapeutic outcomes. The cell-surface RON 
has the potential as a direct drug target or as the delivery 
molecule in combination with chemotherapeutic agents. The 
prospect of clinically targeting RON is currently being ex-
plored by the two main strategies - the development of neu-
tralizing monoclonal antibodies and use of small molecule 
kinase inhibitors. The monoclonal antibodies (mAb) used to 
study the effect of blocking RON signaling pathways in 
CRC include Zt/f2, Zt/g4, Zt/c9 and Zt/c1 and act by induc-
ing receptor internalization followed by protein degradation 
[58-60]. Zt/g4 and Zt/c9 both recognize epitopes on the sema 
sequence while Zt/f2 binds with epitopes on the IPT domain. 
It was observed that these mAb show a synergistic effect 
 
Fig. (1). The ligand-independent activation of RON leads to a constitutively active signaling pathway. The figure is representative of the 
know signaling pathways regulating the tumorigenic potential CRC. 
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wherein a combination of any two mAbs shows a synergistic 
response with concomitant higher RON internalization and 
degradation. Further treatment with neutralizing mAbs in 
addition to down regulating RON-ȕ chain expression also 
inhibits the expression of pro-RON. It was observed that 
treatment with Zt/f2 causes tumor regression in as early as 
five days of administration in xenograft mouse model [60]. 
An in vitro assay shows that although the antibody induces 
the phosphorylation of RON receptor initially it subsequently 
leads to receptor internalization and thus favourable biologi-
cal outcomes. Further Zt/f2 potentiates the effect of chemo-
therapeutic drug 5-florouracil. The tumor growth inhibitory 
effect is observed in both immune competent BALB/c mice 
and athymic nude mice deficient in T-cell mediated immu-
nity. Treatment with mAb Zt/g4 was shown to affect the 
ability of colon cancer cells for colony formation in soft agar 
and increase the chemo-sensitivity of SW620 cells in re-
sponse to gemcitabine treatment [58]. The therapeutic effi-
cacy of blocking RON with monoclonal antibodies has also 
been tested in combination with other chemotherapeutic 
drugs. Zt/g4 and Zt/c1 were tested for their ability to be used 
as a drug carrier by coating them with immunoliposome 
(ILP) and loading with cytotoxic drug doxorubicin (Dox) 
[59, 61]. It was observed that both Anti-RON Zt/g4 and 
Zt/c1 antibodies were highly effective in selectively killing 
colon cancer cells than pegylated liposome doxorubicin.  
 Further the anti-tumorigenic activities of anti-RON-
DOX-IL were evaluated in hypoxic cancer cells HCT116 
and SW620 cells [61]. It is believed that the hypoxic condi-
tions of the tumor microenvironment induce a drug resis-
tance phenotype to the cancer cells [62]. Therefore the thera-
peutic utility of anti-RON-DOX-IL conjugate was evaluated 
under hypoxic conditions. It was observed that anti-RON-
DOX-IL treated HCT116 and SW620 cells have reduced 
IC50 over administration of DOX or DOX-IL. These effects 
were found to be dependent on hypoxic RON expression 
further strengthening the utility of targeting RON signaling 
pathway in CRC. Another RON binding antibody 
IMC41A10 developed by ImClone Systems has been shown 
to block the interaction between RON and its ligand MSP 
with a high affinity [63]. The efficacy of RON kinase has 
been demonstrated in several cancers including HT29 colon 
cancer cells wherein IMC41A10 has been shown to inhibit 
MSP induced phosphorylation and downstream signaling 
events. IMC41A10 is also shown to inhibit the HCA7 colon 
cell migration in response to MSP. Further the anti-tumor 
activity of IMC41A10 was shown in xenograft mouse model 
of HT-29 wherein it showed 50-60% inhibition in tumor 
growth as a single agent [63]. Anti-RON directed receptor 
internalization represents an analogous situation where cells 
control the level of responsiveness to extracellular signals by 
inducing endocytosis of the receptor. Consequently therapeu-
tic exploitation of this natural feedback mechanism to deliver 
cytotoxic drugs represents a promising novel approach com-
bining inactivation of RON signaling with tumor cell killing 
thereby increasing the effectiveness of the therapy. The use 
of mAb in therapeutic targeting of RON suffers limitation in 
case of tumors where RON is activated in a ligand-
independent manner as antibody presumably acts by block-
ing the interaction between RON and MSP [63]. Moreover 
certain variants of RON are present in the cytoplasm and 
consequently not amenable to antibody directed therapies. 
Therefore a small-molecule kinase inhibitor is expected to 
have broader application in RON-driven CRC. The small 
molecule inhibitors described so far for RON also inhibit 
closely related c-Met kinase. Several SMI such as quinoline 
based compound from Amgen, BMS-777607 from Bristol-
Myers Squib and compound I have been described to inhibit 
RON/cMet kinase [64]. Compound I has been shown to re-
sult in partial inhibition of HT-29 colon xenografts [65]. 
However the high sequence similarity between the catalytic 
domains of these kinases makes the design of specific inhibi-
tors challenging [5].  
RON IN TUMOR MICROENVIRONMENT 
 Several studies have demonstrated that aberrant RON 
activity on tumor cells leads to their increased tumorigenic 
potential. However the role of RON in tumor microenviron-
ment remains largely unknown. Though RON regulates the 
extent of activation in several populations of tissue macro-
phages whether it has significance in the tumor-associated 
macrophages (TAMs) is not well understood. The classical 
theory of macrophage activation proposes the existence of 
alternative M1 and M2 states of macrophage activation 
where M2 regulates the extent of inflammatory response by 
M1 [66, 67]. In tissue macrophages RON activation is asso-
ciated with inhibiting Th-1 mediated inflammatory response 
to injury and inflammation. RON signaling suppresses sev-
eral hallmarks of M1 polarized macrophages such as iNOS, 
TNF-Į and IL-12. As RON plays active role in attenuating 
the inflammatory response its expression associated with M2 
macrophage sub-population [68].  
 Tumor microenvironment is largely infiltrated by a dis-
tinct macrophages population known as tumor-associated 
macrophages (TAMs) which play significant roles in shaping 
the developing tumor. TAMs participate in carcinogenesis by 
facilitating and maintaining an immuno- suppressive state 
wherein the extent of infiltration by TAMs is positively cor-
related with poor prognosis in many cancers including CRC. 
An important metabolic switch in M1 and M2 polarization is 
Arg1 (arginase1) which is also associated with suppression 
of immune response and a tumor promoting phenotype. Re-
cently it was shown TAMs isolated from RON -/- mice show 
higher expression of Arg1 [68]. Further studies are warranted 
to decipher whether RON plays a similar role in TAMs from 
the CRC. If the immunosuppressive role of RON in TAMs 
holds true in CRC it would further strengthen the efficacy of 
RON targeted anti-cancer therapies.  
FUTURE DIRECTIONS  
 The role of aberrant RON RTK signaling in pathogenesis 
of CRC has been established with previous studies. The exis-
tence of several RON splice variants in CRC makes it a par-
ticularly interesting molecule and needs further exploration. 
Though the occurrence of splice variants have been reported 
in CRC the functional implications of their expression in 
only a small subset of tumor samples remain enigmatic. 
Though RON signaling drives several key processes of neo-
plastic transformation whether colon cancer cells are ad-
dicted to RON activation is presently not known. Several 
kinase inhibitors such as imatinib and geftinib have been 
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very successful in the clinics due to the phenomenon of on-
cogene addiction. Recently it is shown that cross-talk be-
tween RON and MET sustains the oncogene addiction of 
MET [69]. Thus study of the phenomenon of oncogene ad-
diction with reference to RON activation in colon cancer will 
further strengthen the avenues for therapeutic utilization of 
RON RTK. In addition to the targeting of RON kinase in 
cancer cells, an investigation into the biological role of RON 
in TAMs would be highly desirable as non-malignant cells 
are less likely to evolve to a drug resistant phenotype. 
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